Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Lenta increased the number of pet stores

3/13/23 LENT

Ozon agreed to build a 130,000-square-meter warehouse in New Moscow

3/13/23 OZON

Board of Directors of Beluga Group recommended that dividends be paid for 2022

3/13/23 BELU

Moscow Exchange will present a new dividend policy by the end of the third quarter of 2023

3/10/23 MOEX

Board of Directors of MOEX Group (Moscow Exchange) recommended that dividends be paid for 2022

3/10/23 MOEX

Utair resumed flights on four Boeing aircraft after a year's downtime

3/10/23 UTAR

Beluga Group's profit doubled

3/10/23 BELU

MTS acquires 49% of smart turnstile developer

3/10/23 MTSS

Profit of Moscow Exchange grew by 30% by the end of 2022

3/10/23 MOEX

The Colgate-Palmolive announced a quarterly dividend

3/10/23 CL